Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

eptember 30, ------------------ ----------------- (In millions) 2009 2008 2009 2008 ---- ---- ---- ---- Contract research & development revenue Sanofi-aventis $68.5 $42.0 $178.9 $116.3 Bayer HealthCare 12.2 9.0 34.9 28.2 Other 1.8 1.9 5.3 5.4 --- --- --- --- Total contract research & development revenue $82.5 $52.9 $219.1 $149.9 ===== ===== ====== ======

For the three and nine months ended September 30, 2009 and 2008, contract research and development revenue from sanofi-aventis consisted of the following:

                                      Three months  ended  Nine months ended
                                         September 30,       September 30,
                                       ------------------  -----------------
    (In millions)                       2009        2008     2009       2008
                                        ----        ----     ----       ----
    Aflibercept:
      Regeneron expense reimbursement   $7.0        $7.3    $21.6      $29.3
      Recognition of deferred revenue
       related to up-front payments      2.5         2.1      7.4        6.2
                                         ---         ---      ---        ---
       Total aflibercept                 9.5         9.4     29.0       35.5
                                         ---         ---     ----       ----
    Antibody:
      Regeneron expense reimbursement   55.7        29.5    139.8       72.4
      Recognition of deferred revenue
       related to up-front payment       2.6         2.6      7.9        7
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  XBiotech announced today interim results from its ... US for its anti-cancer agent Xilonix™. ... being evaluated in advanced colorectal cancer patients where ... endpoint of the study is overall survival, comparing ... population provided only palliative therapy for cachexia. ...
(Date:9/2/2014)... CALGARY, Alberta , September 2, 2014 ... der "State of the Art and Featured Research Session" ... Resverlogix Corp. (TSX: RVX) gab heute bekannt, dass Dr. Jan ... beim Kongress des europäischen Kardiologenverbandes (ESC) 2014 in ... In seinem Vortrag mit dem Titel " Effects of ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... , ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 2President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 3President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 4President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 5President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 6President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomen's Association's 2010 Honorable Mentor 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 12ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 13ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 14ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 15ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 16ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 17ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 18ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 19ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 20ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 21ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 22ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results 23
(Date:9/2/2014)... September 02, 2014 Anti-aging is ... and services such as anti-wrinkle treatments and products, ... treatments, and breast augmentation becoming much sought after ... U.S.-based market intelligence firm Transparency Market Research, the ... will grow to USD 191.7 billion by 2019, ...
(Date:9/2/2014)... 02, 2014 Evolve Medical Clinics, ... primary and urgent care arena, is having its ... with a health fair the clinic is sponsoring. ... to assist patients in achieving high quality, convenient ... pricing structure is a groundbreaking change in healthcare. ...
(Date:9/2/2014)... 2014 When weather conditions are right, tornadoes ... leaving behind a path of destruction. In fact, the United ... of 1,253 tornadoes per year. Rainbow International offers the following ... tornado strikes., , Select a safe place ... your home with no windows to stay during the storm. ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated compression ... a luxurious line of graduated compression socks with natural fibers. ... Socks are joining the SIGVARIS MEDICAL collection for those who ... of natural cotton fibers. , “When people step into ... socks as soft as the finest cashmere,” says Clay Walker, ...
(Date:9/2/2014)... 2014 The first trial involving ... implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon get underway, ... District Court, Northern District of Texas, Bernstein Liebhard ... Johnson and its DePuy Orthopaedics unit are facing ... caused recipients to suffer serious and debilitating complications. ...
Breaking Medicine News(10 mins):Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4
... emerged a heartening development.The World Health Organisation (WHO) has ... based Institute for OneWorld Health, a non-profit drug firm, ... ,Paromomycin IM Injection is a cost-effective treatment ... parasitic disease after malaria. ,It is ...
... A new study has found that single tablets containing ... to controlling increasing blood pressure in people with ... ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients ... of researchers led by Ken Jamerson at the University ...
... on stem cells as a cure for infertility has made ... to grow mature sperm from adult stem cells, says Dr.Karim ... Dr. Nayernia, a professor of stem biology at the ... team had successfully coaxed the embryonic stem cells of mice ...
... Calcutta will reach out to more poor people with free ... the three healthcare units we have opened in Kolkata are ... target to reach out to more number of people by ... Gupta told a press conference Tuesday. ,"We have ...
... taken ill Wednesday after inhaling methane gas leaking from a colliery ... leak was reported early morning from the Bathdih colliery of Bharat ... ,The 10 people of Barari Basti area who fell ... to be in critical condition. ,BCCL officials have rushed ...
... girl dragged along by her headlocks, on the ground then, covering ... her head is smashed with a concrete block, blood oozes from ... heard. ,In the eyes of many in her ... was to love a boy from another religion. She was a ...
Cached Medicine News:Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 3Health News:Single-tablet With Two Drugs may Help Control High BP Better 2Health News:Stem Cell Answer to Infertility in Five Years, Says Scientist 2Health News:Women in Iraq More Unsafe Than Ever 2
Monitorr ICP external CSF drainage and monitoring system with patient line one way valve....
... and skull base surgery. Complete implant ... pediatric neurosurgery, bony defects of the ... regions, neuro trauma. Dedicated neuro/skull base ... one compact kit. MRI and CT ...
Ralk Hand Drill, with Jacobs chuck, wrench-locking, with axial channel for Kirschner wires, for twist drills up to 7 mm , for Kirschner wires up to 4 mm...
Hudson Cranial Drill, complete, consisting of: brace; with extension piece and 4 burs...
Medicine Products: